Enlivex Therapeutics Ltd.
ENLV
$1.00
-$0.01-0.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.78% | -53.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.16% | -36.07% | |||
| Operating Income | 12.16% | 36.07% | |||
| Income Before Tax | 45.89% | 33.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.89% | 33.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.89% | 33.31% | |||
| EBIT | 12.16% | 36.07% | |||
| EBITDA | 12.33% | 37.30% | |||
| EPS Basic | 46.11% | 36.85% | |||
| Normalized Basic EPS | 45.67% | 26.71% | |||
| EPS Diluted | 46.67% | 34.81% | |||
| Normalized Diluted EPS | 45.67% | 26.71% | |||
| Average Basic Shares Outstanding | 0.41% | 5.64% | |||
| Average Diluted Shares Outstanding | 0.41% | 5.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||